-$0.59 Earnings Per Share Expected for Aileron Therapeutics Inc (ALRN) This Quarter

Analysts predict that Aileron Therapeutics Inc (NASDAQ:ALRN) will report earnings of ($0.59) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Aileron Therapeutics’ earnings, with estimates ranging from ($0.62) to ($0.55). Aileron Therapeutics posted earnings per share of ($0.52) during the same quarter last year, which indicates a negative year-over-year growth rate of 13.5%. The company is expected to issue its next quarterly earnings report on Monday, April 1st.

According to Zacks, analysts expect that Aileron Therapeutics will report full year earnings of ($1.87) per share for the current year, with EPS estimates ranging from ($2.24) to ($1.58). For the next financial year, analysts forecast that the firm will post earnings of ($1.76) per share, with EPS estimates ranging from ($1.88) to ($1.63). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Aileron Therapeutics.

A number of research analysts have issued reports on ALRN shares. HC Wainwright started coverage on Aileron Therapeutics in a report on Monday, March 11th. They issued a “buy” rating and a $7.00 price target for the company. ValuEngine downgraded Aileron Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Finally, Zacks Investment Research upgraded Aileron Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective on the stock in a report on Thursday, December 27th.

Shares of Aileron Therapeutics stock traded down $0.12 on Monday, reaching $1.83. 248,712 shares of the stock were exchanged, compared to its average volume of 327,070. Aileron Therapeutics has a twelve month low of $0.52 and a twelve month high of $8.43. The company has a market capitalization of $28.76 million, a price-to-earnings ratio of -1.03 and a beta of 3.23. The company has a quick ratio of 4.23, a current ratio of 4.23 and a debt-to-equity ratio of 0.19.

In other news, major shareholder Bioventures Ltd Novartis sold 190,338 shares of Aileron Therapeutics stock in a transaction on Friday, March 15th. The stock was sold at an average price of $2.06, for a total value of $392,096.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 16.10% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the company. Deutsche Bank AG grew its holdings in Aileron Therapeutics by 432.9% in the 4th quarter. Deutsche Bank AG now owns 129,170 shares of the company’s stock worth $108,000 after buying an additional 104,932 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Aileron Therapeutics in the third quarter worth approximately $137,000. Parkwood LLC acquired a new stake in Aileron Therapeutics in the third quarter worth approximately $149,000. Vanguard Group Inc lifted its position in Aileron Therapeutics by 8.0% in the third quarter. Vanguard Group Inc now owns 96,415 shares of the company’s stock worth $265,000 after purchasing an additional 7,109 shares during the period. Finally, Bridgeway Capital Management Inc. lifted its position in Aileron Therapeutics by 78.6% in the third quarter. Bridgeway Capital Management Inc. now owns 113,600 shares of the company’s stock worth $312,000 after purchasing an additional 50,000 shares during the period. 9.16% of the stock is owned by institutional investors and hedge funds.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.

Recommended Story: The benefits and drawbacks of dollar cost averaging

Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.